In the SEER-Medicare observational study, men receiving GnRH agonists had a significantly increased risk of incident diabetes (adjusted HR, 1.44; p < 0.001), coronary heart disease (adjusted HR, 1.16; p < 0.001), and myocardial infarction (adjusted HR, 1.11; p < 0.03) [32] compared to men not receiving treatment. Here, GNRH1 is linked to myocardial infarction.